scholarly journals Az angiotenzinkonvertálóenzim-gátló/kalciumcsatorna-blokkoló fix gyógyszer-kombinációk egyéves perzisztenciája hypertoniában

2019 ◽  
Vol 160 (9) ◽  
pp. 343-348
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci ◽  
Ervin Finta ◽  
Iván Igaz ◽  
Sándor Balogh ◽  
...  
Keyword(s):  
Enzyme Inhibitor ◽  
Patient Adherence ◽  
Therapeutic Option ◽  
Fixed Dose ◽  
Insurance Fund ◽  
Channel Blockers ◽  
Prescription Database ◽  
Hypertensive Patients ◽  
One Year ◽  
The One

Abstract: Introduction: The most recent European guidelines for the treatment of hypertension suggest the use of renin-angiotensin-aldosterone system antagonists (RAAS inhibitors) and calcium channel blockers (CCBs) or diuretics fixed-dose combinations (FDCs) as the first therapeutic option. In antihypertensive therapy, the patient’s adherence is one of the most important factors in reducing unwanted cardiovascular events. Aim: Our aim was to assess the one-year persistence of angiotensin-converting enzyme inhibitor (ACEI) and CCB FDCs in hypertensive patients. Method: Authors have analysed the prescription database of the National Health Insurance Fund in Hungary on pharmacy claims between October 1, 2012 and September 30, 2013. Those patients were identified who filled prescriptions for FDCs of ACEI and CCBs prescribed for the first time for hypertensive patients and who had not received similar drugs during the year before. Apparatus of survival analysis was used, where ‘survival’ was the time to abandon the medication. Results: 124 388 patients met the inclusion criteria. One-year persistence rate and hazard ratio (HR) of discontinuation in patients with ramipril/amlodipine FDC was 54% (HR = 1.00, reference), perindopril/amlodipine 47% (HR = 1.30, p<0.0001), lisinopril/amlodipine 36% (HR = 1.79, p<0.0001), ramipril/felodipine 26% (HR = 2.28, p<0.0001) and trandolapril/verapamil 12% (HR = 4.13, p<0.0001). The average survival time of drug limited to 360 days was 270.2 days for ramipril/amlodipine FDC, 242.7 days for perindopril/amlodipine FDC, 211.2 days for lisinopril/amlodipine FDC, 186.3 days for ramipril/felodipine FDC and 125.7 days for trandolapril/verapamil FDC. Conclusions: The authors demonstrated that the one-year persistence of ACEI/CCB FDCs was significantly different in hypertensive patients. Ramipril/amlodipine FDC was more advantageous for patient adherence. Orv Hetil. 2019; 160(9): 343–348.

P4561Patients adherence with fixed dose combinations of renin-angiotensin-aldosterone system inhibitors in hypertension

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
G A Simonyi ◽  
T Ferenci ◽  
E Finta ◽  
S Balogh ◽  
M Medvegy
Keyword(s):  
Renin Angiotensin System ◽  
Fixed Dose ◽  
Channel Blockers ◽  
Hypertensive Patients ◽  
Renin Angiotensin ◽  
Pharmacy Claims ◽  
Persistence Rate ◽  
Significant Difference ◽  
One Year ◽  
Ras Inhibitors

Abstract Introduction The latest ESC/ESH guidelines recommended fixed dose combinations (FDC) for first therapy in hypertension. Preferred two-drug combinations are a RAS (renin–angiotensin system) blocker with a CCBs (calcium channel blockers) or a diuretic. There are no available data about these FDCs adherence in hypertension. Aim To assess one year persistence of recommended FDCs (RAS-inhibitors/CCBs or diuretics) in hypertensive patients. Method Prescriptions database of National Health Insurance Found in Hungary on pharmacy-claims were analysed between October 1, 2012 and September 30, 2013. We identified patients who filled prescriptions for FDCs of RAS-inhibitors/CCBs or diuretics prescribed for the first time in hypertensive patients who have not received similar drugs during one year before. To model the persistence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. Results 443,149 patients met the inclusion criteria. One-year persistence rate and hazard ratio (HR) of discontinuation (reference was ACEi/indapamide FDC) in patients with ACEi/CCB FDCs (n=124,154) was 44,95% (HR=0.69, [CI: 0.68–0.69], p<0.0001), ARB/HCT FDCs (n=109,707) was 42,52% (HR=0.80, [CI: 0.81–0.83], p<0.0001), ACEi/indapamide FDC (n=127,757) was 37,27% (HR=1.00, reference), ARB/CCB FDCs (n=13,542) was 29.04% (HR=1.19, [CI: 1.17–1.22], p<0.0001) and ACEi/HCT FDCs (n=67,989) was 27.47% (HR=1.17, [CI: 1.15–1.18], p<0.0001). One year peristence of FDCs Conclusions We have found significant difference between FDC s of RAS-inhibitors in hypertensive in relation of patients adherence. Our result demonstrated that ACEi/CCBs FDC therapy has the best one year persistence rate.

scholarly journals A ramipril versus ramipril/amlodipin fix kombináció egyéves perzisztenciája hypertoniás betegekben

2017 ◽  
Vol 158 (42) ◽  
pp. 1669-1673 ◽  
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Blood Pressure ◽  
Survival Analysis ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Persistence Rate ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In the treatment of hypertension avoiding adverse cardiovascular complications to achieve target blood pressure is essential. The appropriate drug selection, and if necessary to change to combination therapy, patients adherence is important which may help fixed dose combination. Aim: The aim of the authors was to investigate the one year adherence of the ramipril and ramipril/amlodipine fixed dose combination in hypertensive patients. Method: Prescriptions database of the National Health Insurance Fund in Hungary on pharmacy-claims was analysed between October 1, 2012 and September 30, 2013. The authors identified patients who filled prescriptions for ramipril monotherapy and fixed dose combinations of ramipril/amlodipine prescribed for the first time in hypertensive patients who have not received similar drugs in the previous year. To model the adherence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: 92,546 patients met the inclusion criteria. During the trial period, ramipril therapy or ramipril/amlodipine fixed dose combination was started in 82,251 and 10,295 patients, respectively. One year persistence rate in patients with ramipril was 30% and 54% in patients with ramipril/amlodipine fixed dose combination therapy. Considering only the 360-day study period, the mean duration of persistence was 189.9 days in patients on ramipril and 270.6 days on ramipril/amlodipine fixed dose combination therapy. The hazard of discontinuation was more than twofold higher during treatment with ramipril compared with the use of the ramipril/amlodipine fixed dose combination therapy (HR = 2.11 [95% CI: 2.05–2.17], p<0,001). Conclusions: There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension. The result demonstrated that ramipril/amlodipine fixed dose combination therapy has a better one year persistence rate. When the next step is necessary to achieve target blood pressure, ramipril/amlodipine fixed dose combination therapy is preferable. Orv Hetil. 2017; 158(42): 1668–1673.

scholarly journals A perindopril/amlodipin szabad és fix kombinációk egyéves terápiahűsége

2017 ◽  
Vol 158 (36) ◽  
pp. 1421-1425
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci ◽  
Mihály Medvegy ◽  
Roland Gasparics ◽  
Ervin Finta
Keyword(s):  
Survival Analysis ◽  
Antihypertensive Therapy ◽  
Patient Adherence ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Cardiovascular Risk Reduction ◽  
Pharmacy Claims ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In management of hypertension patient adherence is one of the most important factors. In hypertension the cardiovascular risk reduction can be reached only by prolonged and effective pharmacotherapy. Aim: To evaluate the persistence of one-year treatment of free and fixed-dose combination of perindopril/amlodipine in hypertension. Method: Information from the National Health Insurance of Hungary prescriptions database on pharmacy claims between October 1, 2012 and September 30, 2013 was analysed. Authors identified patients who filled prescriptions for free and fixed-dose combination of perindopril/amlodipine, prescribed for the first time for hypertension. Patients have not received antihypertensive therapy with similar active substances during the one year before. Apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied. Results: 109,248 patients met the inclusion criteria. Combination antihypertensive therapy with perindopril/amlodipine was started with a free or a fixed-dose combination of these agents in 19,365 and 89,883 patients, respectively. One year persistence rate in patients taking perindopril/amlodipine as a free combination was 27.15%, whereas it was 46.89% in those on the fixed-dose combination. Mean duration of persistence was 177.6 days in patients on the perindopril/amlodipine free, whereas 245.7 days on fixed-dose combination. Actual rate of discontinuation was approximately twice higher with the treatment of free, compared with the use of the fixed-dose combination (hazard ratio =1.94 [95% CI: 1.91–1.98], p<0.001). Orv Hetil. 2017; 158(36): 1421–1425.

scholarly journals Emerging resistance of van genotype in enterococci: A potential menace for therapeutic failure

2019 ◽  
Vol 35 (6) ◽  
Author(s):  
Hasan Ejaz
Keyword(s):  
Culture Media ◽  
Therapeutic Option ◽  
Therapeutic Failure ◽  
Pcr Assay ◽  
Creative Commons ◽  
Multiplex Pcr Assay ◽  
Vancomycin Resistant ◽  
One Year ◽  
The One ◽  
Open Access Article

Objectives: Emerging cases of vancomycin-resistant enterococci (VRE) are detrimental for the patients. The current study aimed to ascertain the occurrence of VRE, their antibiogram and the van genotype responsible for vancomycin resistance. Methods: A total number of 2,958 clinical specimens were processed at Microbiology Department of the Alrazi Health Care, Lahore during the one year (2016-2017) using microbiological culture media, biochemical and serology. Antibiogram of enterococcal strains was performed using disc diffusion and E-test. ATCC Enterococcus faecalis 29212 was used as a quality control strain. The detection of van genotypes was accomplished by multiplex PCR assay. Results: Out of the 147 enterococci, 139 (94.6%) were E. faecalis, and 8 (5.4%) were E. faecium. Statistically significant associations of urine (p < 0.001), pus (p < 0.001) and wound swabs (p = 0.001) were observed with E. faecalis. A significant correlation of enterococcal infections (p = 0.05) was seen with female patients. Four (2.9%) strains of E. faecalis found to be VRE with vanB (75%) and vanA (25%) genotypes. Conclusion: The emerging strains of VRE (vanB and vanA genotype) in the current study are a potential menace for therapeutic failure, which left the physicians with only linezolid as a therapeutic option. doi: https://doi.org/10.12669/pjms.35.6.1145 How to cite this:Ejaz H. Emerging resistance of van genotype in enterococci: A potential menace for therapeutic failure. Pak J Med Sci. 2019;35(6):1659-1663. doi: https://doi.org/10.12669/pjms.35.6.1145 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals A metformin-monoterápia és a szitagliptin/metformin fix kombináció egyéves perzisztenciája

2016 ◽  
Vol 157 (16) ◽  
pp. 618-622
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Metformin Monotherapy ◽  
Dose Combination ◽  
One Year ◽  
The One ◽  
Type 2 Diabetic

Introduction: In treatment of type 2 diabetes mellitus it is important to reach glycaemic targets. The elements of this are the adequate diet and the patient’s adherence to medication. Aim: The aim of the authors was to investigate the one year persistence of the metformin monotherapy and sitagliptin/metformin fixed dose combination in type 2 diabetic patients. Method: National Health Insurance Found prescriptions database of Hungary on pharmacy-claims between October 1, 2012 and September 30, 2013 was analyzed. The authors identified patients who filled prescriptions for metformin monotherapy and fixed dose combinations of sitagliptin/metformin prescribed for the first time. Patients have not received similar drugs one year previous to study. To model the persistence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: During the trial period, metformin monotherapy or sitagliptin/metformin fixed dose combination was started in 63,386 and 10,039 patients, respectively. One year persistence rate in patients with metformin monotherapy was 30%, and 58% in patients with sitagliptin/metformin fixed dose combination. Considering only the 360-day study period, the mean duration of persistence was 173.4 days in patients on metformin monotherapy and 261.9 days on sitagliptin/metformin fixed dose combination. The hazard of discontinuation was more than twofold higher during treatment with metformin monotherapy compared with the use of the sitagliptin/metformin fixed dose combination (hazard ratio = 2.267, p<0.001). Conclusions: There is a significant difference between the one year persistence of metformin monotherapy and sitagliptin/metformin fixed dose combination in type 2 diabetic patients. The result demonstrated sitagliptin/metformin fixed dose combination has a favourable patients’ adherence as compared to metformin monotherapy. Orv. Hetil., 2016, 157(16), 618–622.

scholarly journals A Study of Morphological Changes in Renal Afferent Arterioles Induced by Angiotensin II Type 1 Receptor Blockers in Hypertensive Patients

2020 ◽  
Vol 45 (2) ◽  
pp. 194-208 ◽  
Author(s):  
Yohko Nagai ◽  
Fumito Yamabe ◽  
Yosuke Sasaki ◽  
Takamasa Ishii ◽  
Kazushige Nakanishi ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Enzyme Inhibitor ◽  
Morphological Changes ◽  
Medical Center ◽  
Statistical Significance ◽  
Antihypertensive Agents ◽  
Channel Blockers ◽  
Hypertensive Patients ◽  
Receptor Blockers

Background: Renin-angiotensin-aldosterone system blockers are known to reduce hypertrophy of vascular smooth muscle cells (SMCs) in hypertensive cases. However, we have reported marked proliferative changes of renal afferent arteriolar SMCs in rats induced by a long-term administration of angiotensin II type 1 receptor blockers (ARBs) and an angiotensin-converting enzyme inhibitor (ACEI). In this study, we examined the morphological changes of afferent arteriolar walls in human kidneys with or without ARBs/ACEIs. Methods: Forty-four wedge resections were taken from patients aged 45–74 years from 92 nephrectomized kidneys due to malignancy at Toho University Omori Medical Center between 2013 and 2016. They were divided into the following three groups: 18 hypertensive patients treated with antihypertensive agents including ARBs or ACEIs (the HTARB group), 6 hypertensive patients treated with calcium channel blockers without ARBs/ACEIs (the HTCCB group), and 20 normotensive patients (the normotensive group) as a control. Cases expecting vascular changes such as diabetes were excluded. In each case renal arterioles were measured as the ratio of inner/outer arteriolar diameter, and pathologists estimated morphological abnormal changes, scoring each specimen independently. Results: The ratio in the HTARB group was 0.39 ± 0.05 (mean ± SD), and was significantly the lowest among the three groups (0.46 ± 0.02 in the HTCCB, 0.53 ± 0.02 in the normotensive group; p = 0.0107 vs. HTCCB, p = 0.00001 vs. normotensive). The ratio in the three groups significantly correlated with the estimated glomerular filtration rate (r = 0.4915, p < 0.0007). The afferent arteriolar SMCs in the HTARB group frequently showed marked proliferative and irregular changes. The score of SMC abnormalities estimated regarding the proliferation, irregularity of the arrangement, and size in hilar afferent arteriolar SMCs was highest in the HTARB group and showed statistical significance (p = 0.0088, p = 0.00001, and p = 0.025 versus other two groups). Conclusions: We consider that these morphological changes in arterioles are induced by ARBs/ACEIs. These changes could induce an important suppression of glomerular hyperfiltration and could lead to glomerular ischemia. However, the clinical consequences of these morphological changes in correlation with ARBs/ACEIs were not sufficiently clear and require further analysis. We should consider renal arteriolar morphological changes when using ARBs/ACEIs.

scholarly journals Efficacy of bariatric surgery in a Colombian population

2020 ◽  
Author(s):  
Claudia Y. Obando León ◽  
William Otero Regino ◽  
HERNANDO MARULANDA FERNANDEZ ◽  
Hernán Ballén ◽  
Elder Otero
Keyword(s):  
Bariatric Surgery ◽  
Antihypertensive Drugs ◽  
Adjustable Gastric Band ◽  
Hypertensive Patients ◽  
Risk Of Mortality ◽  
Before And After ◽  
Excess Bmi Loss ◽  
One Year ◽  
The One

Abstract Background Obesity (OB) is defined as having a body mass index (BMI) of ≥ 30 kg/m2. It has a high risk of mortality due to its association with comorbidities. Bariatric surgery (BS) is indicated for a BMI of 40 kg/m2 or of 35 kg/m2 if concurrent with a metabolic disorder. Methods A retrospective observational study of patients subjected to BS, such as Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and adjustable gastric band (AGB). A survey was applied to determine the BMI and patterns of comorbidities before and after BS. Results The study included 30 patients who underwent 25 RYGB, 4 SG and 1 AGB procedures. A total of 17 patients were evaluated at the one-year follow-up and all showed improvement in comorbidities and weight loss, with a mean excess BMI loss (%EBMIL) of 89.5% At the two-year follow-up, 3 patients reported a %EBMIL of 75%. At the three-year follow-up, 10 patients had a %EBMIL of 70.8%%, but 70% (7/10) still had a BMI > 30 kg/m2. Type 2 diabetes mellitus resolved in all (12/12) and the doses of antihypertensive drugs were reduced in 86.4% of hypertensive patients (11/13). Half of the patients followed a diet. Conclusion In our service, BS was effective one year after the procedure. After three years, BMI > 30 kg/m2 persisted in 70% of patients All diabetics were cured. The doses of antihypertensives were lowered in 86.4% of hypertensive patients. Ultrasound scan detected no fatty liver diseases at the one-year follow-up of 85.7% of patients.

Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period

2005 ◽  
Vol 11 (1_suppl) ◽  
pp. 34-36 ◽  
Author(s):  
Kristjan Port ◽  
Kairit Palm ◽  
Margus Viigimaa
Keyword(s):  
Home Monitoring ◽  
Initial Study ◽  
Self Monitoring ◽  
Major Barrier ◽  
Hypertensive Patients ◽  
Study Population ◽  
Measurement Devices ◽  
Two Phases ◽  
One Year ◽  
The One

We evaluated daily self-monitored blood pressure (BP) data collected over one year using remote home monitoring. Fifty treated, moderately hypertensive subjects (26 males, mean age 50 years; 17 females, mean age 54 years; seven exclusions) were recruited for the study in which semi-automatic arm-cuff BP measurement devices were used. The daily self-monitoring regimen had two phases of usage: one of initial enthusiasm (the first one to two months) followed by a phase of lower usage (89% versus 64%, P<0.01). Monitoring was missed more often (P<0.01) during weekends (7.3 instances per patient) compared with workdays (5.0). Lack of motivation was not considered to be a major barrier. Approximately half of the study population was willing to continue the trial at the end of the one-year study. The occurrence of extreme BP values dropped significantly after the initial study month (P=0.02). In conclusion, routine remote BP monitoring is capable of collecting consistent and accurate data, with sufficient sensitivity to reveal trends.

Sign in / Sign up

Export Citation Format

Share Document